SAVA
Filana Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.32
+2.33%Price chart
Jul 15Jul 20Jul 23Jul 28Jul 31Aug 5Aug 10Aug 13
Key dataAug 13, 2026
Open$0.93
From 52W high−71.55%
Volume68429.00
Market cap$63.75M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataAug 13, 2026
Open
$0.93
From 52W high
−71.55%
Volume
68429.00
Market cap
$63.75M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
0.3x
P/E (TTM)
—
RSI (14)
38.8
MomentumView details →
1D Return
+2.33%
YTD Return
−52.68%
SummaryUpdated Dec 1, 2025
Cassava Sciences, Inc. (NASDAQ:SAVA) is a clinical-stage biotechnology company founded in 1998 and originally incorporated as Pain Therapeutics, Inc. before changing its name in March 2019. Based in Austin, Texas, the company has pivoted from pain management to focus exclusively on developing treatments for neurodegenerative diseases, particularly Alzheimer's disease. The company went public in 2000 and has spent over two decades developing its lead drug candidate, simufilam, which is currently in Phase 3 clinical trials for Alzheimer's disease treatment.
Similar companies
Latest newsMore news →
Filana Therapeutics, Inc. received a Nasdaq notice dated September 17, 2026 that it no longer complies with the minimum bid price requirement under Listing Rule 5550(a)(2), giving it until March 16, 2027 to regain compliance.2d agoFilana Therapeutics reported financial results for the second quarter ended June 30, 2026.53d ago